Peritoneal dialysis and inflammation

Area of Science:

• Nephrology
• Biomaterials Science
• Inflammation Research

Background:

• Peritoneal dialysis (PD) is a vital kidney replacement therapy for end-stage renal disease (ESRD).
• PD patients face elevated mortality due to chronic peritoneal dysfunction, including inflammation, fibrosis, and neoangiogenesis.
• The type of peritoneal dialysis solutions (PDSs) used significantly influences the inflammatory process.

Purpose of the Study:

• To review different types of PDSs used in PD.
• To explore the relationship between PDSs and systemic/intraperitoneal inflammation.
• To assess the biocompatibility and inflammatory impact of various PDS formulations.

Main Methods:

• Literature review of existing studies on PD and PDSs.
• Analysis of PDS types: conventional, neutral pH with low glucose degradation products (GDPs), icodextrin, and taurine-containing solutions.
• Evaluation of reported biocompatibility and inflammatory markers associated with each PDS type.

Main Results:

• Some studies suggest neutral pH PDSs with low GDPs, icodextrin, or taurine exhibit better biocompatibility and less inflammation than conventional solutions.
• Evidence indicates these newer PDS formulations may have a lower influence on the inflammatory process.
• However, current studies often involve small populations and short durations.

Conclusions:

• While certain PDSs show promise for reduced inflammation, conclusive evidence is limited.
• Further large-scale, well-designed clinical trials are essential.
• Definitive understanding of PDS role in inflammation requires more robust research in chronic PD patients.